CY1115565T1 - Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος - Google Patents
Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματοςInfo
- Publication number
- CY1115565T1 CY1115565T1 CY20141100763T CY141100763T CY1115565T1 CY 1115565 T1 CY1115565 T1 CY 1115565T1 CY 20141100763 T CY20141100763 T CY 20141100763T CY 141100763 T CY141100763 T CY 141100763T CY 1115565 T1 CY1115565 T1 CY 1115565T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glaucoma
- treatment
- composition
- hyperence
- eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία οφθαλμική υδατική σύνθεση η οποία περιέχει ανάλογα της ΡGF2α για την αγωγή της οφθαλμικής υπερτάσεως και του γλαυκώματος, σε μία μέθοδο αγωγής της οφθαλμικής υπερτάσεως και του γλαυκώματος μέσω της χορηγήσεως της εν λόγω συνθέσεως σε ένα άτομο το οποίο χρήζει μίας τέτοιας αγωγής, και σε μία μέθοδο για την αύξηση της υδατοδιαλυτότητας και της σταθερότητας των αναλόγων της ΡGF2α σε μία υδατική σύνθεση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08397513A EP2127638A1 (en) | 2008-05-30 | 2008-05-30 | Method and composition for treating ocular hypertension and glaucoma |
EP09754864.8A EP2306977B1 (en) | 2008-05-30 | 2009-05-28 | Method and composition for treating ocular hypertension and glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115565T1 true CY1115565T1 (el) | 2017-01-04 |
Family
ID=39940592
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100763T CY1115565T1 (el) | 2008-05-30 | 2014-09-18 | Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος |
CY20171100675T CY1120351T1 (el) | 2008-05-30 | 2017-06-27 | Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100675T CY1120351T1 (el) | 2008-05-30 | 2017-06-27 | Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος |
Country Status (27)
Country | Link |
---|---|
US (3) | US9999593B2 (el) |
EP (7) | EP2127638A1 (el) |
JP (9) | JP2011521943A (el) |
KR (5) | KR102114401B1 (el) |
CN (1) | CN102083413B (el) |
AR (2) | AR071937A1 (el) |
AU (1) | AU2009252210C1 (el) |
BR (1) | BRPI0913109B8 (el) |
CA (2) | CA2965185A1 (el) |
CY (2) | CY1115565T1 (el) |
DK (4) | DK2772249T3 (el) |
EA (1) | EA023661B1 (el) |
ES (5) | ES2808050T3 (el) |
GE (1) | GEP20156220B (el) |
HR (4) | HRP20220361T1 (el) |
HU (3) | HUE058079T2 (el) |
JO (1) | JO3039B1 (el) |
LT (3) | LT3205334T (el) |
MX (1) | MX2010012987A (el) |
MY (1) | MY159463A (el) |
PL (4) | PL3714877T3 (el) |
PT (4) | PT2772249T (el) |
SG (1) | SG191628A1 (el) |
SI (4) | SI2772249T1 (el) |
TW (1) | TWI432202B (el) |
UA (1) | UA102257C2 (el) |
WO (1) | WO2009145356A1 (el) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI544927B (zh) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
JP5681472B2 (ja) * | 2009-12-28 | 2015-03-11 | ロート製薬株式会社 | 眼科用組成物 |
FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
US20130245124A1 (en) * | 2010-07-29 | 2013-09-19 | Allergan, Inc. | Preservative free bimatoprost solutions |
PL2598118T3 (pl) * | 2010-07-29 | 2019-01-31 | Allergan, Inc. | Roztwory bimatoprost i tymolol bez środków konserwujących |
US9061034B2 (en) * | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
EP2618810B1 (en) | 2010-09-21 | 2016-11-23 | S & V Technologies GmbH | Cosmetic composition |
EP2452669A1 (en) * | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
US20120263803A1 (en) * | 2011-04-12 | 2012-10-18 | R-Tech Ueno, Ltd. | Aqueous ophthalmic composition |
CN102716074B (zh) * | 2012-06-28 | 2013-10-16 | 武汉武药科技有限公司 | 一种贝美前列素滴眼剂及其制备方法 |
EP2887923B1 (en) | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
JP2017502089A (ja) | 2014-01-10 | 2017-01-19 | マニスティー パートナーズ エルエルシーManistee Partners Llc | 偏頭痛の処置 |
CN104766952B (zh) * | 2015-04-21 | 2017-01-25 | 武汉凯迪工程技术研究总院有限公司 | 利用生物质气化炉滤渣制备锂离子电池负极材料的方法 |
ES2747302T3 (es) | 2015-06-09 | 2020-03-10 | Medproject Pharma Entw Und Vertriebsgesellschaft Mbh | Gel oftálmico de bimatoprost aplicable en gotas |
US10105371B2 (en) * | 2015-10-09 | 2018-10-23 | Tamara Vrabec | Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject |
US20180325854A1 (en) * | 2015-11-06 | 2018-11-15 | Accuitis Pharmaceuticals, Inc. | Use of proteasome inhibitors to treat ocular disorders |
US10918694B2 (en) | 2016-02-29 | 2021-02-16 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
WO2018033854A1 (en) * | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
KR101770324B1 (ko) | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
CN110494138B (zh) * | 2017-03-27 | 2023-07-11 | 兴和株式会社 | 医药制剂 |
US20180318319A1 (en) * | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
JP6931493B2 (ja) | 2017-06-22 | 2021-09-08 | ヨンスン ファイン ケミカル カンパニー,リミテッド | 緑内障治療用点眼組成物 |
EP4338751A3 (en) * | 2017-12-21 | 2024-05-22 | Santen Pharmaceutical Co., Ltd. | Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor |
EP3820445A1 (en) | 2018-07-09 | 2021-05-19 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic dispensing device |
CN111632025A (zh) * | 2020-03-04 | 2020-09-08 | 吉林大学第一医院 | 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用 |
CN111840225B (zh) * | 2020-08-12 | 2021-09-14 | 陈丽娜 | 一种用于治疗青光眼的滴眼剂及其制备方法 |
RU2761625C2 (ru) * | 2021-02-11 | 2021-12-13 | Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") | Фармацевтическая композиция тафлупроста |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
WO2023241652A1 (zh) * | 2022-06-16 | 2023-12-21 | 广州润尔眼科生物科技有限公司 | 一种药物组合物及其制备方法和应用 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778815A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one |
EP0286903B2 (en) | 1987-04-03 | 2000-03-29 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
JPH0655640A (ja) | 1992-08-04 | 1994-03-01 | Aavan Internatl:Kk | 洗面台カウンター及びその製造方法 |
JPH06107547A (ja) | 1992-10-01 | 1994-04-19 | Aarutetsuku Ueno:Kk | 眼科用組成物 |
AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
JP2510066Y2 (ja) | 1993-01-20 | 1996-09-11 | 東洋製罐株式会社 | 加熱殺菌可能な液体医薬容器 |
US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
AU704938B2 (en) * | 1995-11-17 | 1999-05-06 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
EP0930296B2 (en) | 1996-09-17 | 2005-11-02 | Asahi Glass Company Ltd. | Fluorinated prostaglandin derivatives and medicines |
EP0944530A1 (en) | 1996-12-09 | 1999-09-29 | Bausch & Lomb Incorporated | Single-use flexible container |
JP3480549B2 (ja) | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
ES2265166T3 (es) * | 1997-10-13 | 2007-02-01 | R-Tech Ueno, Ltd. | Composicion para tratamiento de hipertension intraocular o glaucoma. |
US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
GB2337740B (en) | 1998-05-26 | 2000-11-15 | Spreckelsen Mcgeough Ltd | Fluid packaging |
ATE285795T1 (de) | 1998-07-14 | 2005-01-15 | Alcon Mfg Ltd | Polypropylenbasierte behälter für prostaglandin- enthaltende produkte |
US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
EP1115406A4 (en) | 1998-09-25 | 2003-03-05 | Alcon Lab Inc | SUSTAINABLE RELEASE OPHTHALMIC COMPOSITION AND METHOD OF EYE THERAPY |
US6096783A (en) | 1998-12-15 | 2000-08-01 | Alcon Laboratories, Inc. | Cyclobutane prostaglandin analogues as ocular hypotensive agents |
AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
DK1466889T3 (da) | 1999-04-06 | 2008-09-08 | Sepracor Inc | O-Desmethylvenlafaxin-succinat |
CN1232305C (zh) | 2000-06-19 | 2005-12-21 | 参天制药株式会社 | 防腐剂 |
JP3876355B2 (ja) | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
EP1321144B1 (en) | 2000-09-13 | 2010-12-08 | Santen Pharmaceutical Co., Ltd. | Eye drops |
TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
WO2004006826A1 (ja) | 2002-07-16 | 2004-01-22 | Senju Pharmaceutical Co., Ltd. | 薬液容器及びその製造方法 |
AU2003261981A1 (en) * | 2002-09-09 | 2004-03-29 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
ATE450264T1 (de) * | 2003-07-31 | 2009-12-15 | Santen Pharmaceutical Co Ltd | Prostaglandin enthaltendes produkt |
US20050287325A1 (en) | 2004-06-25 | 2005-12-29 | Pharmacia & Upjohn Company | Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients |
ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
US7562796B2 (en) | 2004-11-24 | 2009-07-21 | Holopack International Corp. | Dispensing container with flow control system |
JP2006187602A (ja) | 2004-12-09 | 2006-07-20 | Santen Pharmaceut Co Ltd | 分子内にフッ素原子を有するプロスタグランジン含有製品 |
CN101175496A (zh) * | 2004-12-24 | 2008-05-07 | 参天制药株式会社 | 含有前列腺素F2α衍生物的制品 |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
ES2393675T3 (es) * | 2005-07-13 | 2012-12-27 | Santen Pharmaceutical Co., Ltd. | Composición conservante para uso oftálmico |
WO2007015510A1 (ja) | 2005-08-02 | 2007-02-08 | Santen Pharmaceutical Co., Ltd. | 熱的に不安定な薬物の分解抑制方法 |
CA2625568C (en) | 2005-10-10 | 2013-10-08 | Novagali Pharma Sa | Ophthalmic emulsions containing prostaglandins |
FI126233B (sv) | 2006-02-23 | 2016-08-31 | Oy Kwh Mirka Ab | Oscillerande slipmaskin |
FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
KR100927617B1 (ko) | 2007-11-26 | 2009-11-23 | 한국표준과학연구원 | 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법 |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
-
2008
- 2008-05-30 EP EP08397513A patent/EP2127638A1/en not_active Withdrawn
-
2009
- 2009-05-19 TW TW098116503A patent/TWI432202B/zh active
- 2009-05-27 JO JOP/2009/0192A patent/JO3039B1/ar active
- 2009-05-28 HU HUE20164602A patent/HUE058079T2/hu unknown
- 2009-05-28 BR BRPI0913109A patent/BRPI0913109B8/pt active IP Right Grant
- 2009-05-28 EP EP23202597.3A patent/EP4289446A3/en active Pending
- 2009-05-28 HU HUE14001862A patent/HUE033103T2/en unknown
- 2009-05-28 CA CA2965185A patent/CA2965185A1/en not_active Abandoned
- 2009-05-28 AR ARP090101912A patent/AR071937A1/es not_active Application Discontinuation
- 2009-05-28 SI SI200931694T patent/SI2772249T1/sl unknown
- 2009-05-28 KR KR1020197016340A patent/KR102114401B1/ko active IP Right Grant
- 2009-05-28 ES ES17000440T patent/ES2808050T3/es active Active
- 2009-05-28 GE GEAP200912045A patent/GEP20156220B/en unknown
- 2009-05-28 DK DK14001862.3T patent/DK2772249T3/en active
- 2009-05-28 LT LTEP17000440.2T patent/LT3205334T/lt unknown
- 2009-05-28 EP EP21217057.5A patent/EP4035656B1/en active Active
- 2009-05-28 SI SI200932073T patent/SI3205334T1/sl unknown
- 2009-05-28 CN CN2009801197245A patent/CN102083413B/zh active Active
- 2009-05-28 EP EP14001862.3A patent/EP2772249B1/en not_active Revoked
- 2009-05-28 EP EP09754864.8A patent/EP2306977B1/en active Active
- 2009-05-28 CA CA2724194A patent/CA2724194C/en active Active
- 2009-05-28 PL PL20164602T patent/PL3714877T3/pl unknown
- 2009-05-28 US US12/995,351 patent/US9999593B2/en active Active
- 2009-05-28 KR KR1020107029072A patent/KR101650006B1/ko active IP Right Grant
- 2009-05-28 KR KR1020187001130A patent/KR101988642B1/ko active IP Right Grant
- 2009-05-28 PT PT140018623T patent/PT2772249T/pt unknown
- 2009-05-28 ES ES09754864.8T patent/ES2495316T3/es active Active
- 2009-05-28 HU HUE17000440A patent/HUE049923T2/hu unknown
- 2009-05-28 UA UAA201015619A patent/UA102257C2/uk unknown
- 2009-05-28 PT PT97548648T patent/PT2306977E/pt unknown
- 2009-05-28 PL PL17000440T patent/PL3205334T3/pl unknown
- 2009-05-28 PT PT201646023T patent/PT3714877T/pt unknown
- 2009-05-28 EP EP20164602.3A patent/EP3714877B1/en active Active
- 2009-05-28 MX MX2010012987A patent/MX2010012987A/es active IP Right Grant
- 2009-05-28 LT LTEP14001862.3T patent/LT2772249T/lt unknown
- 2009-05-28 SG SG2013041751A patent/SG191628A1/en unknown
- 2009-05-28 KR KR1020167022210A patent/KR101820816B1/ko active IP Right Grant
- 2009-05-28 WO PCT/JP2009/060211 patent/WO2009145356A1/en active Application Filing
- 2009-05-28 KR KR1020207014211A patent/KR102246598B1/ko active IP Right Grant
- 2009-05-28 PL PL14001862T patent/PL2772249T3/pl unknown
- 2009-05-28 DK DK20164602.3T patent/DK3714877T3/da active
- 2009-05-28 JP JP2011511256A patent/JP2011521943A/ja active Pending
- 2009-05-28 SI SI200932159T patent/SI3714877T1/sl unknown
- 2009-05-28 SI SI200931050T patent/SI2306977T1/sl unknown
- 2009-05-28 EP EP17000440.2A patent/EP3205334B1/en active Active
- 2009-05-28 ES ES20164602T patent/ES2907982T3/es active Active
- 2009-05-28 PT PT170004402T patent/PT3205334T/pt unknown
- 2009-05-28 MY MYPI2010005463A patent/MY159463A/en unknown
- 2009-05-28 DK DK17000440.2T patent/DK3205334T3/da active
- 2009-05-28 DK DK09754864.8T patent/DK2306977T3/da active
- 2009-05-28 HR HRP20220361TT patent/HRP20220361T1/hr unknown
- 2009-05-28 LT LTEP20164602.3T patent/LT3714877T/lt unknown
- 2009-05-28 ES ES21217057T patent/ES2968837T3/es active Active
- 2009-05-28 ES ES14001862.3T patent/ES2627837T3/es active Active
- 2009-05-28 AU AU2009252210A patent/AU2009252210C1/en active Active
- 2009-05-28 EA EA201071413A patent/EA023661B1/ru unknown
- 2009-05-28 PL PL09754864T patent/PL2306977T3/pl unknown
-
2014
- 2014-04-22 JP JP2014088256A patent/JP2014133765A/ja active Pending
- 2014-09-18 CY CY20141100763T patent/CY1115565T1/el unknown
- 2014-10-14 HR HRP20140979AT patent/HRP20140979T1/hr unknown
-
2015
- 2015-12-07 JP JP2015238594A patent/JP6148317B2/ja active Active
-
2017
- 2017-05-18 JP JP2017098843A patent/JP6356868B2/ja active Active
- 2017-05-23 HR HRP20170769TT patent/HRP20170769T1/hr unknown
- 2017-06-27 CY CY20171100675T patent/CY1120351T1/el unknown
-
2018
- 2018-06-14 JP JP2018113647A patent/JP6649992B2/ja active Active
- 2018-06-18 US US16/010,739 patent/US10864159B2/en active Active
- 2018-11-01 AR ARP180103181A patent/AR120961A2/es not_active Application Discontinuation
-
2020
- 2020-01-17 JP JP2020005799A patent/JP6889789B2/ja active Active
- 2020-06-24 HR HRP20200998TT patent/HRP20200998T1/hr unknown
- 2020-11-11 US US17/094,986 patent/US20210059931A1/en not_active Abandoned
-
2021
- 2021-05-21 JP JP2021085839A patent/JP7265584B2/ja active Active
-
2023
- 2023-04-14 JP JP2023066348A patent/JP2023085558A/ja active Pending
-
2024
- 2024-04-12 JP JP2024064531A patent/JP2024079852A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115565T1 (el) | Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος | |
CY1122366T1 (el) | Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας | |
CY1120079T1 (el) | Υδατικη συνθεση που περιεχει βρωμεξινη | |
CY1121032T1 (el) | Παραγωγα εξενδινης-4 ως επιλεκτικοι αγωνιστες υποδοχεα γλυκαγονης | |
CY1121360T1 (el) | Αναστολεις dna-pk | |
CY1124789T1 (el) | Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων | |
CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
CY1123051T1 (el) | Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους | |
CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
EA201001491A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
CY1115690T1 (el) | Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων | |
CY1121787T1 (el) | Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
EA201791467A1 (ru) | Водный офтальмологический раствор | |
UY32457A (es) | Vacuna del virus del dengue inactivado | |
BR112015027477A2 (pt) | método para tratamento de um transtorno de deglutição | |
CY1122081T1 (el) | Διαλυματα τα οποια περιλαμβανουν πολυαιθυλενογλυκολη και ηλεκτρολυτες | |
CY1116802T1 (el) | Ετεροκυκλικες ενωσεις | |
EA201190337A1 (ru) | Способ лечения |